Clinigen increases its 2017 interim dividend by 23%

DividendMax Ltd.

Clinigen increases its 2017 interim dividend by 23%


Adjusted gross profit up 34% driven by organic growth across all divisions, a full six months contribution from Link Healthcare and currency benefits

Adjusted EPS up 31% to 19.0p (2015: 14.5p)

Interim dividend increased 23% to 1.6p (2015: 1.3p)

Excellent performances by Link Healthcare and Clinical Trial Services

Launch of Japanese business, enhancing licensed and unlicensed presence in Asia

Global Access added further exclusive supply agreements

First contracts converted from Managed Access to Global Access

Shaun Chilton, Group Chief Executive Officer of Clinigen, said:

"We have delivered another strong half of progress, achieving more than 30% growth across all our key financial measures.

"Link Healthcare has achieved an outstanding performance, demonstrating the value of the acquisition. Clinical Trial Services delivered another excellent performance whilst Managed Access and Specialty Pharma continued to see strong growth. It is particularly pleasing that all the divisions contributed well to the growth.

"Our focus now is to capitalise on our international market leading positions and the geographical footprint we have built. We will also look for selective bolt-on acquisitions to enhance our product portfolio, geographical footprint and / or service capabilities.

"We have started the second half positively and are well positioned to complete another year of strong growth."

Companies mentioned